Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Ovarian cancer is the second leading cause of death from gynecologic malignancies worldwide. Management of platinum-resistant disease is challenging and clinical outcomes with standard chemotherapy are poor. Over the past decades, significant efforts have been made to understand drug resistance and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Ochoa, Eduardo, Veneziani, Ana C, Oza, Amit M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
A novel strategy for the treatment of cancer: antibody drug conjugates - Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387675/
https://www.ncbi.nlm.nih.gov/pubmed/37528890
http://dx.doi.org/10.1177/11795549231187264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387675/
https://www.ncbi.nlm.nih.gov/pubmed/37528890
http://dx.doi.org/10.1177/11795549231187264

Ejemplares similares